Sigma-1 Receptor Agonism, ER Stress, and Fluvoxamine in Long COVID / ME/CFS
1 Reis et al. 2026 — REVIVE-TOGETHER RCT: Fluvoxamine for Long COVID Fatigue
Full Citation:: Reis G, Silva EASM, Silva DCM, Thabane L, et al. The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial. Annals of Internal Medicine. 2026. DOI:: 10.7326/ANNALS-25-03959 Published:: March 31, 2026 Trial Name:: REVIVE-TOGETHER Study Design:: Bayesian adaptive platform RCT, 3-arm (fluvoxamine vs. metformin vs. placebo) Sample Size:: 399 adults; Long COVID fatigue ≥90 days post-confirmed SARS-CoV-2, Brazil Duration:: 60 days treatment, 90 days follow-up Key Findings::
- Primary outcome (FSS day 60): fluvoxamine −0.43 (95% CrI −0.80 to −0.07); 99.0% posterior probability of superiority over placebo
- Day-90 follow-up: −0.58 (CrI −0.98 to −0.16); 99.7% posterior probability — effect sustained after stopping
- Quality of life (EQ-5D-5L): improvements at days 30, 60, and 90
- Metformin: no benefit (mean diff −0.03; 56.0% PP); arm halted early for futility
- Adverse events: fluvoxamine 20.0% vs.\ metformin 28.8% vs.\ placebo 29.7%
- No biomarkers measured; sigma-1/neuroinflammation mechanism not directly testedConclusion:: Fluvoxamine produces statistically robust reduction in Long COVID fatigue; metformin does not. Mechanism attributed to non-SERT pharmacology (sigma-1 agonism, ER stress suppression, ASM inhibition) but not empirically tested in the trial. Limitations:: Baseline imbalance (placebo higher baseline fatigue and proportion female); differential dropout (13% fluvoxamine vs. 6% placebo at day 90); modest absolute effect size; CYP1A2/caffeine confound not addressed; Long COVID population, not formally ME/CFS; PEM, cognitive outcomes, and orthostatic intolerance not assessed. Certainty:: 0.65 (strong Bayesian RCT; mechanistic attribution remains uncertain; methodological caveats temper) Integrated into:: Chapter 18 (Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy)
2 Hashimoto 2021 — Sigma-1 Receptor as Drug Repurposing Target in COVID-19
Full Citation:: Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. European Archives of Psychiatry and Clinical Neuroscience. 2021;271(2):249–258. DOI:: 10.1007/s00406-020-01231-x PMID:: 33159562 Key Findings::
- Fluvoxamine has the highest S1R affinity among commercially available SSRIs: Ki ≈ 36 nM (vs.\ 240 nM fluoxetine; >4,000 nM sertraline/paroxetine)
- S1R agonism stabilises ER proteostasis; suppresses IRE1α-mediated splicing of XBP-1 mRNA, dampening the unfolded protein response
- S1R agonism attenuates downstream NF-κB-driven cytokine storm (IL-6, TNF-α)
- Theoretical basis for class-within-class difference in SSRI efficacy on COVID/Long COVID outcomesConclusion:: Among SSRIs, fluvoxamine’s unique S1R affinity profile makes it the strongest candidate for repurposing in ER-stress-mediated post-infectious conditions. Limitations:: Mechanistic review, not clinical trial; most evidence from cell models and animal studies; clinical dose sufficiency for S1R occupancy is inferred, not measured. Certainty:: 0.60 (strong mechanistic review; S1R Ki rankings well-established; clinical implications extrapolated) Integrated into:: Chapter 18 (Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy, Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy)
3 Lenze et al. 2020 — Fluvoxamine Prevents Clinical Deterioration in Acute COVID-19
Full Citation:: Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(22):2292–2300. DOI:: 10.1001/jama.2020.22760 PMID:: 33180147 Study Design:: Double-blind RCT; fluvoxamine 100 mg three times daily vs. placebo; 15 days Sample Size:: 152 (80 fluvoxamine, 72 placebo) Key Findings::
- Clinical deterioration: 0/80 (0%) fluvoxamine vs.\ 6/72 (8.3%) placebo; $p$=0.009
- No serious adverse events in fluvoxamine arm
- Authors attribute benefit to sigma-1 receptor agonism suppressing cytokine storm rather than SERT inhibitionConclusion:: First RCT evidence that fluvoxamine prevents clinical deterioration in acute COVID-19; establishes sigma-1 mechanism in COVID context, predating the post-acute (Long COVID) evidence. Limitations:: Small sample; event rate low (6 events); 15-day duration; sigma-1 mechanism inferred, not measured; cytokine/inflammatory biomarkers not collected. Certainty:: 0.60 (peer-reviewed RCT in top journal; small sample; mechanism inferential) Integrated into:: Chapter 18 (Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy)
4 Gordon et al. 2020 — SARS-CoV-2 Interactome: Nsp6 and Nsp8 Bind Sigma-1 Receptor
Full Citation:: Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468. DOI:: 10.1038/s41586-020-2286-9 PMID:: 32353859 Study Design:: Affinity purification mass spectrometry interactome mapping; 26 of 29 SARS-CoV-2 proteins expressed in HEK293T/17 cells Key Findings::
- 332 high-confidence protein–protein interactions between SARS-CoV-2 and human proteins
- Nsp6 and Nsp8 (ER-localized replication proteins) directly bind sigma-1 receptor (SIGMAR1)
- This interaction provides molecular basis for SARS-CoV-2 co-opting ER proteostasis machinery
- 69 existing FDA-approved drugs and investigational compounds target the identified interactions
- Sigma-1 ligands identified as drug repurposing candidates from the interactome dataConclusion:: SARS-CoV-2 directly engages sigma-1 receptor via two viral proteins, establishing the molecular basis for ER stress induction and the mechanistic rationale for S1R agonism as therapy. Limitations:: Cell line overexpression system (HEK293T); interactions may not fully replicate in primary infection context; functional consequences of Nsp6/Nsp8–S1R binding not yet directly tested in ME/CFS. Certainty:: 0.75 (landmark Nature paper; affinity purification is rigorous; cell-line caveat for in vivo translation) Integrated into:: Chapter 18 (Sigma-1 Receptor Mechanisms and Fluvoxamine Therapy)
5 Smith & Verkman 2018 — Critique of the Glymphatic Hypothesis
Full Citation:: Smith AJ, Verkman AS. The “glymphatic” mechanism for solute clearance in Alzheimer’s disease: game changer or unproven speculation? FASEB Journal. 2018;32(2):543–551. DOI:: 10.1096/fj.201700999 PMID:: 28935817 Study Design:: Methodological review and critique Key Findings::
- The proposed bulk convective flow of cerebrospinal fluid through perivascular spaces is physically inconsistent with the high hydraulic resistance of brain parenchyma
- Tracer spread in the original glymphatic studies is more parsimoniously explained by diffusion than bulk convection
- AQP4 knockout studies used to support the glymphatic model have been replicated inconsistently
- The glymphatic framework may be an experimental artefact of dye injection techniquesConclusion:: The specific mechanism of aquaporin-4-dependent bulk flow may be incorrect; associations between sleep and brain waste clearance may reflect other SWS-dependent processes (diffusion, metabolic rate reduction, extracellular space expansion). Limitations:: Review paper without new experimental data; focused on Alzheimer’s context; subsequent studies continue to debate the question. Certainty:: 0.50 (methodological critique; expert-level; does not resolve the empirical debate but raises important cautions) Integrated into:: Chapter 18, glymphatic hypothesis caveat (Additional Integrative Topics)
6 Schultheiss & Bolte 1985 — Anti-ANT Autoantibodies in Dilated Cardiomyopathy
Full Citation:: Schultheiss HP, Bolte HD. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology. 1985;17(6):603–617. DOI:: 10.1016/S0022-2828(85)80029-8 PMID:: 2991541 Study Design:: Cross-sectional immunological study; n=18 histologically confirmed DCM patients; controls: coronary heart disease, alcoholic heart disease, healthy donors Key Findings::
- 17/18 (94%) DCM patients showed significant binding to isolated adenine nucleotide translocase (ANT)
- Zero positive results in all control groups (coronary disease, alcoholic cardiomyopathy, healthy donors)
- Organ-specific antigenic determinants confirmed by crossed immunoelectrophoresis and immunoadsorption
- Functionally active antibodies decreased ADP/ATP exchange rate from cardiac mitochondria
- Close correlation between antibody titre and hemodynamic function (contractility proxy)Conclusion:: Landmark study establishing ANT as a cardiac autoantigen with functional energy-metabolism consequences. Autoimmunological mechanisms likely contribute to DCM pathogenesis via impaired ATP export. Limitations:: Very small sample (n=18); single uncontrolled study; the 94% prevalence was not replicated at this magnitude in subsequent studies; single-centre German cohort. Certainty:: 0.60 (pioneering peer-reviewed study; foundational; small n and non-replicated extreme prevalence reduce confidence) Integrated into:: G28 integration guide (ANT autoantibodies research stream)
7 Schultheiss 1989 — ADP/ATP Carrier Autoantibodies: Pathogenesis Review
Full Citation:: Schultheiss HP. The significance of autoantibodies against the ADP/ATP carrier for the pathogenesis of myocarditis and dilated cardiomyopathy — clinical and experimental data. Springer Seminars in Immunopathology. 1989;11(1):15–30. DOI:: 10.1007/BF00197081 PMID:: 2546261 Study Design:: Review of clinical and experimental evidence Key Findings::
- ADP/ATP carrier (ANT) of the inner mitochondrial membrane identified as autoantigen in myocarditis and DCM
- Autoimmunity to ANT may contribute to DCM as a downstream stage of myocarditis
- Proposes antibody-mediated reduction of cardiac function via energy imbalance between ATP delivery and demand
- Framework linking post-viral autoimmune response to chronic cardiac dysfunctionConclusion:: Synthesises the Schultheiss program of research; establishes conceptual framework for ANT autoimmunity as a pathogenic mechanism in post-viral cardiomyopathy. Limitations:: Review without new primary data; abstract not available in PubMed; quantitative details not confirmable from available metadata. Certainty:: 0.50 (review paper; historically important; details not independently verifiable from abstract) Integrated into:: G28 integration guide (ANT autoantibodies research stream)
9 Takemoto et al. 1993 — Anti-ANT Prevalence in DCM and Myocarditis
Full Citation:: Takemoto M, Kusachi S, Urabe N, Inoue K, Tsuji T. Auto-antibody against adenine nucleotide translocator in dilated cardiomyopathy and myocarditis: incidence and relation to cardiac function and morphology. Japanese Circulation Journal. 1993;57(12):1150–1158. DOI:: 10.1253/jcj.57.1150 PMID:: 8283607 Study Design:: Cross-sectional study; DCM n=37, myocarditis n=12, control cardiac diseases and healthy controls Key Findings::
- Anti-ANT antibodies detected in 6/37 (16%) DCM patients and 5/12 (42%) myocarditis patients
- Negative in all control and other cardiac disease groups --- high specificity confirmed
- No statistically significant correlation between anti-ANT titre and cardiac parameters (LVEF, LVDd, CTR)
- Prevalence much lower than the 94% reported by Schultheiss & Bolte 1985, suggesting methodological and selection differencesConclusion:: Confirms anti-ANT antibodies are specific to cardiac autoimmune disease but prevalence is substantially lower in an independent cohort. The lack of hemodynamic correlation raises questions about pathogenic relevance in all anti-ANT-positive patients. Limitations:: Cross-sectional; Japanese cohort; different methodology from Schultheiss 1985 (explains prevalence discrepancy); LVEF may be insensitive to subtle ATP-export defects. Certainty:: 0.55 (peer-reviewed; larger DCM sample than 1985 paper; non-significant hemodynamic correlation weakens pathogenic claim) Integrated into:: G28 integration guide (ANT autoantibodies research stream)
10 Manchado et al. 2002 — ANT1 Epitope Mapping in Idiopathic DCM
Full Citation:: Manchado C, Orús J, Villarroya F, Roig E, Heras M, Giralt M, Iglesias R, Sanz G, Mampel T, Viñas O. Epitope mapping of mitochondrial adenine nucleotide translocase-1 in idiopathic dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology. 2002;34(5):571–582. DOI:: 10.1006/jmcc.2002.1538 Study Design:: Immunological epitope mapping study; IDCM n=45 patients Key Findings::
- 16/45 (36%) IDCM patients had anti-ANT1 antibodies above control levels
- Primary epitopes located in C-terminal 146 amino acids of ANT1
- Most significant epitopes in M2 and M3 hydrophilic loops (membrane-facing regions of ANT1)
- At least three distinct epitopes identified
- Distinguishes IDCM from ischemic cardiomyopathy by antibody profileConclusion:: Provides structural basis for ANT1 autoimmunity; membrane-facing loop regions are both functionally essential for ATP/ADP exchange and immunogenically accessible. Relevant for assay design in ME/CFS research — antigen preparation should include C-terminal and loop regions. Limitations:: IDCM only; epitope accessibility in vivo (serum vs. intact mitochondrial membrane) not fully established; PMID not confirmed from available source text. Certainty:: 0.60 (peer-reviewed; provides mechanistic depth; moderate sample; in vivo epitope accessibility caveat) Integrated into:: G28 integration guide (ANT autoantibodies research stream)
11 Mendel-Hartvig et al. 1986 — Anti-ANT Lacks Disease Specificity (Null Finding)
Full Citation:: Mendel-Hartvig I, Frostell A, Nelson BD. Primary biliary cirrhosis: assessment of the quantitative importance of the adenine nucleotide translocator protein as a major mitochondrial antigen. Clinical and Experimental Immunology. 1986;66(2):399–405. PMID:: 3028680 Study Design:: Specificity assessment study; PBC patients, SLE patients, chronic active hepatitis, healthy controls Key Findings::
- PBC antibodies bind to rat liver ANT by ELISA and immunoblotting
- SLE patients and chronic active hepatitis patients show comparable or higher anti-ANT titres than PBC patients
- Healthy controls show measurable anti-ANT reactivity at comparable levels
- Conclusion: rat liver ANT is NOT a specific antigen for PBC autoantibodiesConclusion:: Critical null/specificity finding for G28 research design. Anti-ANT antibodies measured against rat liver ANT lack disease specificity. Any ME/CFS anti-ANT assay must use isoform-specific human cardiac ANT1 antigen with strict thresholds and full control panels to avoid false-positives. Limitations:: Uses rat liver ANT (predominantly ANT2); cross-reactivity patterns may differ with human cardiac ANT1; historical (1986) ELISA methods less sensitive than modern platforms. Certainty:: 0.65 (well-designed specificity study; directly relevant to assay design; antigen-species caveat is important) Integrated into:: G28 integration guide (null findings section; establishes what has and has not been tested)
12 Nilsson et al. 2020 — ME/CFS Metabolic Dysfunction Not Due to Anti-Mitochondrial Antibodies
Full Citation:: Nilsson I, Palmer J, Apostolou E, Gottfries J, Rizwan M, Dahle C, Rosén A. Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies. Frontiers in Medicine. 2020;7:108. DOI:: 10.3389/fmed.2020.00108 PMID:: 32296708 Study Design:: Cross-sectional; 161 ME/CFS patients (3 cohorts) + 44 healthy donors + 15 PBC + 14 fibromyalgia + 29 MS patients Key Findings::
- Only 1/161 ME/CFS patients positive for anti-PDC (pyruvate dehydrogenase complex); vs.\ 15/15 PBC patients positive
- General anti-mitochondrial antibodies (inner and outer membrane by IIF) negative in ME/CFS cohort
- Anti-cardiolipin (IgG/IgM/IgA) not significantly different from healthy donors
- CRITICAL CAVEAT: anti-ANT was NOT specifically tested; assay used general IIF on rat tissue sections, not ANT-specific ELISA
- Metabolic dysfunction in ME/CFS is not explained by the anti-mitochondrial autoantibodies testedConclusion:: Important partial null finding. ME/CFS metabolic dysfunction is not driven by anti-PDC, anti-cardiolipin, or general AMA. However, this study does not close the G28 gap because ANT-specific ELISA with human cardiac ANT1 was not performed. The IIF screening method lacks the sensitivity and specificity for detecting low-titre ANT-targeted antibodies. Limitations:: Anti-ANT not specifically tested (critical gap); IIF may miss low-titre ANT-specific antibodies; rat tissue substrate for IIF may not display human ANT1 epitopes equivalently. Certainty:: 0.70 (robust multi-cohort study; well-controlled; null finding is genuine but incomplete for G28 specifically) Integrated into:: G28 integration guide (null findings section; establishes what has and has not been tested)
13 Germain et al. 2025 — Comprehensive Autoantibody Profiling in ME/CFS: No Significant Differences
Full Citation:: Germain A, Jaycox JR, Emig CJ, Ring AM, Hanson MR. An In-Depth Exploration of the Autoantibody Immune Profile in ME/CFS Using Novel Antigen Profiling Techniques. International Journal of Molecular Sciences. 2025;26(6):2799. DOI:: 10.3390/ijms26062799 PMID:: 40141440 Study Design:: Cross-sectional; n=172 unique participants (up to 95 ME/CFS, 69 controls); Oncimmune/Augmenta Luminex (1,134 autoantibodies) + REAP (6,183 extracellular proteins + 225 viral antigens) Key Findings::
- No significant differences in any of 1,134 autoantibody reactivities between ME/CFS and controls (Luminex panel)
- No elevation in beta2-adrenergic, alpha1A-adrenergic, or muscarinic receptor antibodies (contradicts Loebel 2016)
- Elevated herpesvirus antigen reactivity in ME/CFS: EBV gp42 and HSV1 gL
- CRITICAL CAVEAT: REAP covers extracellular proteome only; intramitochondrial proteins (ANT, PDC) excluded by platform design
- Anti-ANT was NOT measured in this studyConclusion:: Most comprehensive null finding for autoantibodies in ME/CFS to date; contradicts GPCR autoantibody findings. Platform limitation means intramitochondrial targets including ANT remain unaddressed. Supports viral reactivation hypothesis via herpesvirus antigen reactivity. Limitations:: REAP restricted to extracellular proteome; ANT and inner mitochondrial membrane proteins not assessable; discrepancy with Loebel 2016 may reflect assay differences; cannot address G28. Certainty:: 0.65 (rigorous multi-platform study; large panel; methodological caveat for intramitochondrial targets) Integrated into:: G28 integration guide (null findings/platform limitations section)
14 Schreiner et al. 2020 — HHV-6 Reactivation and Mitochondrial Fragmentation in ME/CFS
Full Citation:: Schreiner P, Harrer T, Scheibenbogen C, Lamer S, Schlosser A, Naviaux RK, Prusty BK. Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. ImmunoHorizons. 2020;4(4):201–215. DOI:: 10.4049/immunohorizons.2000006 PMID:: 32327453 Study Design:: Mechanistic study; n=10 ME/CFS patient serum samples in cell culture adoptive transfer assays Key Findings::
- HHV-6 reactivation induces mitochondrial fragmentation via miR-aU14/miR-30/p53/DRP1 axis
- Adoptive transfer of ME/CFS patient serum reproduced mitochondrial fragmentation in recipient cells
- HHV-6 reactivation strongly inhibits pyruvate dehydrogenase and fatty acid oxidation enzymes
- 1-carbon metabolism, dUTPase, and thymidylate synthase strongly induced
- Mitochondrial fragmentation associated with severely compromised energy metabolism and antiviral cell danger responseConclusion:: ME/CFS patient serum contains transferable factor(s) sufficient to induce mitochondrial fragmentation. Mitochondrial fragmentation disrupts cristae architecture and may impair ANT function indirectly. Provides mechanistic link between viral reactivation, structural mitochondrial damage, and energy failure. ANT not directly measured. Limitations:: n=10; in vitro serum transfer model; HHV-6 mechanism not universally confirmed; ANT not directly assessed; transferable factor not identified. Certainty:: 0.55 (peer-reviewed; mechanistically novel; small n and in vitro model limit translation) Integrated into:: G28 integration guide (indirect mitochondrial fragmentation mechanism)
15 Chen et al. 2023 — ANT Isoforms: Comprehensive Review
Full Citation:: Chen Y, Wu L, Liu J, Ma L, Zhang W. Adenine nucleotide translocase: Current knowledge in post-translational modifications, regulations and pathological implications for human diseases. FASEB Journal. 2023;37:e22953. DOI:: 10.1096/fj.202201855RR PMID:: 37224026 Study Design:: Systematic review Key Findings::
- ANT1: heart/skeletal muscle/brain; pro-apoptotic; primary ATP exporter; mutations cause Sengers syndrome (exercise intolerance, cardiomyopathy, lactic acidosis)
- ANT2: liver and proliferating cells; anti-apoptotic; ATP importer in glycolytic mode
- ANT3: ubiquitously expressed; constitutive baseline transporter
- ANT4: germ cells only
- Post-translational modifications (acetylation, nitrosylation, glutathionylation, carbonylation) impair transport activity
- Disease associations: diabetes, heart disease, Parkinson's, Sengers syndrome, cancer (isoform shift), Alzheimer's, Progressive External Ophthalmoplegia, FSHDConclusion:: Definitive reference for ANT isoform biology. Sengers syndrome (ANT1 loss-of-function) produces exercise intolerance and lactic acidosis highly analogous to ME/CFS PEM, supporting ANT1 as highest-priority target for G28 investigation. Post-translational modifications provide additional mechanism by which ANT1 could be impaired without autoantibodies. Limitations:: Review only; no ME/CFS discussion; autoantibodies not addressed. Certainty:: 0.75 (peer-reviewed review; comprehensive isoform coverage; FASEB Journal) Integrated into:: G28 integration guide (ANT isoform biology and disease precedent)
16 Dörner et al. 2006 — ANT Isoform Shift Halves ATP Transport Capacity in DCM
Full Citation:: Dörner A, Giessen S, Gaub R, Grosse Siestrup H, Schwimmbeck PL, Hetzer R, Poller W, Schultheiss HP. An isoform shift in the cardiac adenine nucleotide translocase expression alters the kinetic properties of the carrier in dilated cardiomyopathy. European Journal of Heart Failure. 2006;8(1):81–89. DOI:: 10.1016/j.ejheart.2005.05.003 PMID:: 16107323 Study Design:: Comparative expression and kinetics study in DCM cardiac tissue vs. controls Key Findings::
- DCM hearts show upregulation of ANT1 with downregulation of ANT2 (relative isoform shift)
- Maximum ADP/ATP transport velocity: 1112±178 (controls) vs.\ 498±113 micromol/min/g in DCM (55% reduction)
- ATP binding affinity Km shifted from 90.4 to 104.3 microM in DCM
- G1409T polymorphism in ANT2 not associated with DCM or functional impairment
- No autoantibody measurements in this studyConclusion:: ANT expression-level changes (isoform shift) independently produce a severe (~55%) reduction in ATP transport capacity in diseased cardiac tissue. In ME/CFS, ANT1 expression changes may compound any autoantibody-mediated inhibition, suggesting multiple convergent mechanisms at Step 7. Limitations:: DCM cardiac tissue only; no ME/CFS data; no autoantibody measurements; whether similar isoform shifts occur in ME/CFS muscle or PBMCs is unknown. Certainty:: 0.65 (peer-reviewed; quantitatively rigorous; DCM-specific, not ME/CFS) Integrated into:: G28 integration guide (ANT expression-level dysfunction as independent mechanism)
17 Wohlrab et al. 2025 — Autoantibody Targeting Therapies in ME/CFS and Post-COVID
Full Citation:: Wohlrab F, Eltity M, Ufer F, Paul F, Scheibenbogen C, Bellmann-Strobl J. Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome. Expert Opinion on Biological Therapy. 2025;25(5):1–5. DOI:: 10.1080/14712598.2025.2492774 PMID:: 40211686 Study Design:: Editorial review Key Findings::
- Immunoadsorption (IA): removes circulating IgG; 14/20 post-COVID ME/CFS patients improved after 5 IA sessions
- Efgartigimod (FcRn blocker): enhances IgG degradation; reduces total autoantibody burden
- BC007/rovunaptabin: neutralises GPCR autoantibodies; Phase II trials ongoing
- Rituximab (B-cell depletion): inconsistent results in ME/CFS
- Daratumumab (plasma cell depletion): early positive results in small studies
- Primary autoantibody targets discussed: beta2-adrenergic and muscarinic receptors; ANT not discussedConclusion:: Establishes therapeutic toolkit for autoantibody-mediated ME/CFS. If anti-ANT autoantibodies are confirmed, immunoadsorption is the most immediately applicable intervention. Inconsistent results with GPCR-targeted therapies may reflect heterogeneous autoantibody profiles across patients. Limitations:: Editorial; limited primary data summarised; ANT not discussed; no RCT evidence for most approaches; full text behind paywall. Certainty:: 0.50 (editorial; framework rather than evidence; provides therapeutic roadmap only) Integrated into:: G28 integration guide (therapeutic implications section)
18 Calabrese 2002 — Hormesis: Changing View of the Dose-Response
Full Citation:: Calabrese EJ. Hormesis: Changing View of the Dose-Response, a Personal Account of the History and Current Status. Mutation Research. 2002;511(3):181–189. DOI:: 10.1016/S1383-5742(02)00013-3 PMID:: 12088716 Study Design:: Historical review Key Findings::
- Documents hormesis' journey from marginalization to re-emergence in pharmacology/toxicology
- Low doses of chemicals and drugs stimulate biological systems while higher doses inhibit — biphasic dose-response
- Challenges default assumption of linear or threshold dose-response models
- Establishes that hormesis has quantitative features conserved across biological systemsConclusion:: Foundational text establishing that biphasic dose-response is a default biological pattern, not an anomaly. Directly relevant to LDN (low-dose stimulation of compensatory mechanisms), LDA, and ultra-low-dose pharmacology. Limitations:: Review format; no primary data; toxicology focus rather than clinical pharmacology. Certainty:: 0.80
19 Calabrese & Baldwin 2003 — Toxicology Rethinks Its Central Belief
Full Citation:: Calabrese EJ, Baldwin LA. Toxicology Rethinks Its Central Belief. Nature. 2003;421(6924):691–692. DOI:: 10.1038/421691a PMID:: 12610596 Study Design:: Opinion/review in Nature Key Findings::
- Hormesis documented across broad range of species, endpoints, and chemical classes
- The default assumption of linear or threshold dose-response is not empirically supported for many agents
- Recommends regulatory agencies re-evaluate default dose-response assumptionsConclusion:: High-impact venue (Nature) establishing hormesis as a serious scientific challenge to linear dose-response orthodoxy. Key citation for arguing that biphasic dosing effects should be the default expectation in clinical pharmacology. Limitations:: Short format (opinion piece); does not address clinical trial implications. Certainty:: 0.80
20 Calabrese 2008 — The Yerkes-Dodson Law as a Special Case of Hormesis
Full Citation:: Calabrese EJ. Stress Biology and Hormesis: The Yerkes-Dodson Law in Psychology — a Special Case of the Hormesis Dose Response. Critical Reviews in Toxicology. 2008;38(5):453–462. DOI:: 10.1080/10408440802004007 PMID:: 18568865 Study Design:: Historical review and conceptual integration Key Findings::
- The Yerkes-Dodson Law (inverted-U arousal-performance function) is a special case of hormesis where two independent variables interact
- Quantitative features (amplitude, stimulation width, dose range) match hormetic dose-response model
- Integrates psychology's foundational non-monotonic law into the hormesis framework
- Provides evolutionary rationale for why biological systems respond biphasically to stressorsConclusion:: Bridges psychology and toxicology, demonstrating that inverted-U dose-response is a universal biological pattern. Directly relevant to stimulant dosing (modafinil, methylphenidate) where optimal cognitive benefit exists at a narrow mid-range dose with impairment at higher doses. Also applies to HPA axis and beta-blocker dose-response in POTS. Limitations:: Review format; no new primary data; theoretical integration only. Certainty:: 0.80
21 Calabrese 2010 — Hormesis Is Central to Toxicology and Pharmacology
Full Citation:: Calabrese EJ. Hormesis Is Central to Toxicology, Pharmacology and Risk Assessment. Human & Experimental Toxicology. 2010;29(4):249–261. DOI:: 10.1177/0960327109363973 PMID:: 20332169 Study Design:: Systematic review Key Findings::
- Quantitative features of hormetic dose-response: 30--60\% stimulation above control at low doses
- Maximum stimulation width of 10--20 fold dose range
- Hormesis generalizable across species, endpoints, and chemical classes
- Argues that drug development and regulatory science should incorporate biphasic dose-responseConclusion:: Key review documenting the quantitative constraints of hormetic responses. These quantitative features inform dosing windows for LDN (0.5–5mg range), LDA (0.25–2mg), lithium (≈1mg), and melatonin (≈1mg). The narrow dose window explains why clinical trials using standard dosing paradigms may produce null results for hormetic agents. Limitations:: Review format; quantitative features based on toxicological data rather than clinical pharmacology. Certainty:: 0.80
22 Sun et al. 2020 — Yin/Yang Doctrine and Hormesis
Full Citation:: Sun H, Calabrese EJ, Lin Z, Lian B, Zhang X. Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology. Trends in Pharmacological Sciences. 2020;41(8):544–556. DOI:: 10.1016/j.tips.2020.05.004 PMID:: 32564900 Study Design:: Integrative review Key Findings::
- Integrates classical Chinese Yin/Yang philosophy into Western hormesis framework
- Hormesis is generalizable across biological systems, drug classes, and temporal scales
- Time-dependent hormetic features are critical for drug-dosing schedules (e.g., pulsed vs continuous dosing)
- Published in Trends in Pharmacological Sciences (top pharmacology journal)Conclusion:: Broadens hormesis from a toxicological concept to a fundamental principle of drug action. Time-dependent hormesis is especially relevant for drugs with fluctuating receptor occupancy like LDN (4–6 hour blockade window) and intermittent rapamycin. Suggests optimal drug dosing may be non-continuous. Limitations:: Review format; primarily theoretical; limited clinical trial examples. Certainty:: 0.80
23 Arnsten 2011 — Catecholamine Inverted-U in Prefrontal Cortex
Full Citation:: Arnsten AFT. Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks. Biological Psychiatry. 2011;69(12):e89–e99. DOI:: 10.1016/j.biopsych.2011.01.027 PMID:: 21489408 Study Design:: Comprehensive review with mechanistic model Key Findings::
- Dopamine D1 receptor signaling in prefrontal cortex follows an inverted-U dose-response
- Moderate D1 stimulation enhances working memory and cognitive function via cAMP signaling
- Excessive D1 stimulation impairs PFC function by opening HCN channels (cAMP excess)
- Norepinephrine α2A receptors (high affinity, low occupancy) enhance PFC; α1 and β receptors impair at high NE levels
- PFC networks are exquisitely sensitive to catecholamine levels — both deficiency and excess impairConclusion:: Provides the neurobiological mechanism for why modafinil 200mg may improve cognition but 400mg can worsen it (Randall 2005 ME/CFS trial). Also explains why SNRIs (duloxetine) can produce worsening at doses that raise catecholamines beyond the PFC optimal window. The D1 inverted-U is fundamental to understanding any drug that modulates prefrontal dopamine. Limitations:: Primarily animal electrophysiology; human translation is inferential; does not specifically address ME/CFS neuroinflammation context. Certainty:: 0.85
24 Cools & D’Esposito 2011 — Inverted-U Dopamine and Human Cognition
Full Citation:: Cools R, D’Esposito M. Inverted-U-Shaped Dopamine Actions on Human Working Memory and Cognitive Control. Biological Psychiatry. 2011;69(12):e113–e125. DOI:: 10.1016/j.biopsych.2011.03.028 PMID:: 21531388 Study Design:: Comprehensive review integrating pharmacology, genetics, and neuroimaging Key Findings::
- Both excessive and insufficient dopamine impair prefrontal function in humans
- COMT Val158Met genotype interacts with drug dose: Val carriers (higher COMT, lower dopamine) benefit from dopamine agonists; Met carriers (lower COMT, higher dopamine) are impaired
- Striatal dopamine supports cognitive flexibility; prefrontal dopamine supports stability
- The optimal dopamine level is task- and individual-dependentConclusion:: Confirms inverted-U dopamine-cognition relationship in humans via three convergent lines of evidence. Directly relevant to stimulant and SNRI dosing in ME/CFS: patients with different baseline dopamine levels (e.g., via COMT genotype) will have different optimal doses. Explains why uniform dosing produces heterogeneous outcomes. Limitations:: Healthy young adults studied; ME/CFS-specific data absent; genetic interaction data limited to COMT. Certainty:: 0.85
25 Cools & Arnsten 2022 — Neuromodulation of Primate Prefrontal Cortex
Full Citation:: Cools R, Arnsten AFT. Neuromodulation of Prefrontal Cortex Cognitive Function in Primates: The Powerful Roles of Monoamines and Acetylcholine. Neuropsychopharmacology. 2022;47(1):309–328. DOI:: 10.1038/s41386-021-01100-8 PMID:: 34312496 Study Design:: Comprehensive review (Neuropsychopharmacology Reviews series) Key Findings::
- All major neuromodulators (dopamine, norepinephrine, serotonin, acetylcholine) show inverted-U dose-response in primate PFC
- Receptors with different affinities mediate opposing effects: high-affinity receptors (D1, α2A) enhance PFC at low concentrations; low-affinity receptors (D2, α1, β) impair at high concentrations
- Cholinergic (M1) and serotonergic (5-HT1A, 5-HT2A) modulation also follows biphasic patterns
- Individual differences in baseline neuromodulator tone determine optimal doseConclusion:: Most comprehensive review of non-monotonic neuromodulator dose-response in prefrontal circuits. Covers the mechanistic basis for all drugs targeting catecholamines and acetylcholine relevant to ME/CFS cognitive dysfunction (modafinil, methylphenidate, duloxetine, pitolisant, donepezil, atomoxetine). Establishes that biphasic dose-response is the rule for cognitive enhancement, not an exception. Limitations:: Primate electrophysiology; human clinical translation pending; ME/CFS-specific neuroinflammation may alter receptor dynamics. Certainty:: 0.85
26 Sarbassov et al. 2006 — Prolonged Rapamycin Inhibits mTORC2 Assembly
Full Citation:: Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB. Molecular Cell. 2006;22(2):159–168. DOI:: 10.1016/j.molcel.2006.03.029 PMID:: 16603397 Study Design:: In vitro and in vivo mechanistic study Key Findings::
- Initially mTORC2 was thought to be rapamycin-insensitive; this paper demonstrated chronic rapamycin inhibits mTORC2 assembly
- mTORC2 inhibition reduces Akt/PKB phosphorylation, impairing cell survival signaling
- Rapamycin dose and treatment duration determine mTORC1 vs mTORC2 selectivity
- Acute/low-dose rapamycin: primarily mTORC1 inhibition (beneficial anti-aging, anti-inflammatory)
- Chronic/high-dose rapamycin: mTORC2 also inhibited (insulin resistance, immunosuppression)Conclusion:: Foundational paper establishing that rapamycin’s effect is biphasic and dose/duration-dependent. For ME/CFS rapamycin protocols, this implies that intermittent low-dose scheduling may preserve mTORC2 function while achieving therapeutic mTORC1 inhibition. Higher daily dosing risks mTORC2-mediated toxicity. Limitations:: In vitro and mouse models; human dose-selectivity thresholds not precisely established; cancer cell line data may not translate to non-malignant dosing. Certainty:: 0.85
27 Lamming et al. 2012 — Rapamycin-Induced Insulin Resistance via mTORC2 Loss
Full Citation:: Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity. Science. 2012;335(6076):1638–1643. DOI:: 10.1126/science.1215135 PMID:: 22461615 Study Design:: Mouse model mechanistic study Key Findings::
- Chronic rapamycin treatment causes insulin resistance via mTORC2 inhibition in liver
- mTORC1 inhibition mediates longevity benefits; mTORC2 inhibition mediates metabolic toxicity
- These two effects are pharmacologically separable: mTORC2 inhibition is dose and duration-dependent
- Genetic ablation of mTORC1 (raptor) alone does not cause insulin resistanceConclusion:: Paradigmatic example of biphasic dose-response for a single drug with opposing therapeutic (mTORC1) and adverse (mTORC2) effects. Directly informs clinical rapamycin dosing in ME/CFS: lower intermittent doses (e.g., 1–3mg once weekly) may preserve mTORC2 while achieving therapeutic mTORC1 inhibition. Higher daily dosing (e.g., 5–10mg daily) risks mTORC2-mediated metabolic toxicity. Limitations:: Mouse model; human dose thresholds for mTORC2 inhibition are not directly measured; insulin resistance findings may be species-specific. Certainty:: 0.90
28 Ristow & Zarse 2010 — Mitohormesis: Oxidative Stress as Adaptive Signal
Full Citation:: Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Experimental Gerontology. 2010;45(6):410–418. DOI:: 10.1016/j.exger.2010.03.014 PMID:: 20350594 Study Design:: Mechanistic review and conceptual paper Key Findings::
- Mild ROS elevation serves as an essential hormetic signal for PINK1/Parkin-mediated mitophagy, antioxidant gene induction (via Nrf2), and mitochondrial biogenesis
- High-dose antioxidant supplementation during exercise abolishes ROS signaling and can blunt adaptive responses
- This creates a trade-off: antioxidants reduce oxidative damage but may impair mitochondrial quality controlConclusion:: Mitohormesis provides mechanistic basis for the counter-intuitive finding that exercise-induced ROS is beneficial; complete ROS scavenging is not the goal of antioxidant therapy. Limitations:: Primarily mechanistic and animal-model based; dose-response relationships for the ROS threshold in humans are not established; ME/CFS-specific applicability is inferential. Certainty:: 0.60 (established mechanism; widely cited; dose-response in human ME/CFS context is extrapolation) Integrated into:: Chapter 18, Emergency PEM Protocol antioxidant-mitophagy trade-off warning (Practical Warning)
29 Baraniuk et al. 2024 — Meta-analysis of NK Cell Cytotoxicity in ME/CFS
Full Citation:: Baraniuk JN, Eaton-Fitch N, Marshall-Gradisnik S. Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome. Frontiers in Immunology. 2024;15:1440643. DOI:: 10.3389/fimmu.2024.1440643 PMID:: 39483457 Study Design:: Systematic review and meta-analysis; 28 papers, 55 data points on NK cell function Key Findings::
- NK cell cytotoxicity is reduced to approximately half of healthy control levels in ME/CFS
- Overall effect size: Hedges' g = 0.96 (95% CI: 0.75--1.18)
- Described as the most replicated and consistent immune finding in ME/CFS
- Heterogeneity in effect sizes attributable to varying methodology and effector-to-target ratios, not absence of effect
- Dysfunction confirmed across multiple independent research groupsWound Healing Relevance:: NK cells are mechanistically required for wound healing (see Sobecki 2021 and Petri 2017). ME/CFS NK cells are reduced to ~50% functional capacity by the most rigorous meta-analytic standard available. This directly undermines any claim that wound healing proceeds normally in ME/CFS. Limitations:: Meta-analysis of heterogeneous studies; effect size variability; does not directly measure wound healing outcomes. Certainty:: 0.90 (high — large multi-study meta-analysis; well-powered; independent replication across 28 studies) Integrated into:: Wound healing integration guide for ch06-energy-metabolism
30 Sobecki et al. 2021 — NK Cells Mediate a Trade-Off Between Wound Healing and Antibacterial Defence
Full Citation:: Sobecki M, Krzywinska E, Nagarajan S, et al. NK cells in hypoxic skin mediate a trade-off between wound healing and antibacterial defense. Nature Communications. 2021;12:4700. DOI:: 10.1038/s41467-021-25065-w PMID:: 34349124 Study Design:: Mechanistic mouse study; NK cell conditional knockouts and HIF-1alpha pathway manipulation Key Findings::
- NK cells are active, mechanistically required participants in wound closure --- not passive bystanders
- HIF-1alpha in NK cells controls IFN-γ and GM-CSF output, which directly modulates wound healing rate
- NK-cell-derived IFN-γ and GM-CSF impair tissue closure; their absence accelerates healing but impairs bacterial control
- Wound healing is thus directly regulated by NK cell functional stateConclusion:: NK cells are not “downstream” of wound healing; they are upstream regulators. Reducing NK cell output (as in ME/CFS) would shift the balance toward faster initial closure but impaired coordination with immune defense — a plausible mechanism for atypical wound healing in ME/CFS. Limitations:: Mouse model (corneal skin); HIF-1alpha biology in human NK cells may differ; no ME/CFS data. Certainty:: 0.75 (high-quality mechanistic study; Nature Communications; mouse model — human translation indirect) Integrated into:: Wound healing integration guide for ch06-energy-metabolism
31 Xue et al. 2018 — Autonomic Nervous System Modulates Wound Healing via Macrophages
Full Citation:: Xue Y, He J, Xiao C, et al. The mouse autonomic nervous system modulates inflammation and epithelial renewal after corneal abrasion through the activation of distinct local macrophages. Mucosal Immunology. 2018;11(5):1496–1511. DOI:: 10.1038/s41385-018-0031-6 PMID:: 29988115 Study Design:: Mechanistic mouse study with pharmacological sympathetic/parasympathetic manipulation Key Findings::
- Sympathetic nervous system activation inhibits reepithelialization and increases pro-inflammatory neutrophil influx
- Parasympathetic activation promotes tissue repair through anti-inflammatory macrophages (α7-nAChR+)
- Two functionally distinct macrophage subsets identified: β2-AR+ (SNS-responsive, pro-inflammatory) and α7-nAChR+ (PNS-responsive, pro-healing)
- ANS manipulation proposed as therapeutic approach for impaired wound healingConclusion:: ME/CFS is characterized by sympathetic overactivation and parasympathetic withdrawal (documented in POTS, HRV studies). By this mechanism, the autonomic dysfunction of ME/CFS would directly bias wound healing toward the inflammatory/delayed-repair phenotype. Limitations:: Mouse corneal model; epithelial tissue specific; broader wound healing generalization requires caution. Certainty:: 0.70 (strong mechanistic evidence; Mucosal Immunology; mouse model with pharmacological validation) Integrated into:: Wound healing integration guide for ch06-energy-metabolism
32 Barrenas et al. 2019 — Tissue Repair Mechanisms Prevent Immune Exhaustion in SIV
Full Citation:: Barrenas F, Raehtz K, Xu C, et al. Macrophage-associated wound healing contributes to African green monkey SIV pathogenesis control. Nature Communications. 2019;10:5101. DOI:: 10.1038/s41467-019-12987-9 PMID:: 31704931 Study Design:: Transcriptomics and comparative immunology; African green monkeys vs rhesus macaques following SIV infection Key Findings::
- Natural SIV hosts maintain evolutionarily conserved regenerative wound healing mechanisms in mucosal tissue
- Repair/regeneration signature (TGF-β, fibronectin) in macrophages prevents immunopathology
- Failure to activate tissue repair correlates with immune exhaustion and AIDS progression
- Wound healing mechanisms are thus part of normal immune homeostasis, not a separate peripheral processConclusion:: Establishes that tissue repair is actively required for immune homeostasis. Systems with immune exhaustion (ME/CFS analog) have impaired tissue repair as a co-feature, not as a separate problem. Limitations:: Non-human primate model; indirect relevance to ME/CFS; SIV infection is an acute-to-chronic viral challenge, not identical to ME/CFS pathogenesis. Certainty:: 0.70 (Nature Communications; non-human primate; indirect but mechanistically coherent) Integrated into:: Wound healing integration guide for ch06-energy-metabolism
33 Stanojcic et al. 2016 — Immune Exhaustion Phenotype Impairs Wound Healing in Burns
Full Citation:: Stanojcic M, Chen P, Xiu F, Jeschke MG. Impaired Immune Response in Elderly Burn Patients: New Insights Into the Immune-senescence Phenotype. Annals of Surgery. 2016;264(1):195–202. DOI:: 10.1097/SLA.0000000000001408 PMID:: 26649579 Study Design:: Prospective clinical cohort; n = 130 burned patients (94 adults, 36 elderly) + 10 controls Key Findings::
- Immune exhaustion phenotype in elderly patients produces blunted early inflammatory response followed by hyperinflammation
- Outcomes: significantly elevated sepsis rates and mortality despite smaller burn sizes
- Pattern characterized as NK cell exhaustion, dysregulated cytokine profiles, impaired early wound immune response
- Authors conclude immune exhaustion is a primary mediator of poor wound repair and mortalityConclusion:: The immune exhaustion phenotype (which ME/CFS shares: halved NK cytotoxicity, TGF-β elevation, persistent immune activation) produces clinically documented impairment of wound healing responses. This is the closest clinical analog to predict wound healing impairment in ME/CFS. Limitations:: Burn patients are not ME/CFS patients; elderly immune senescence is a different mechanism from ME/CFS immune exhaustion; direct causal chain requires additional bridging studies. Certainty:: 0.70 (clinical; adequately powered cohort; burn injury model — immune mechanism plausibly transferable) Integrated into:: Wound healing integration guide for ch06-energy-metabolism
34 Petri et al. 2017 — TGF-β and IL-6 Lock NK Cells into Regulatory Wound-Repair Circuit
Full Citation:: Petri RM, Hackel A, Hahnel K, et al. Activated Tissue-Resident Mesenchymal Stromal Cells Regulate the Immune Response in the Tumor Microenvironment. Stem Cell Reports. 2017;9(3):985–998. DOI:: 10.1016/j.stemcr.2017.06.020 PMID:: 28781075 Study Design:: In vitro mechanistic study; poly(I:C) stimulation of MSC-NK co-cultures Key Findings::
- TGF-β and IL-6 drive NK cells into a regulatory senescent-like state at later timepoints of injury response
- Regulatory NK cells then provide pro-angiogenic feedback to MSCs, supporting tissue repair
- Early type I IFN from MSCs first enhances NK cytotoxicity; late TGF-β terminates it
- This time-dependent circuit is essential for controlled, phase-appropriate wound healingConclusion:: In ME/CFS, chronically elevated TGF-β and IL-6 may constitutively activate the suppressive arm of this circuit, locking NK cells in a non-cytotoxic regulatory state and disrupting the temporal sequencing required for normal wound healing. This could produce both impaired infection clearance and premature inflammatory resolution. Limitations:: In vitro only; tumor microenvironment context; NK-MSC interactions in wound healing may differ; ME/CFS application is inferential. Certainty:: 0.60 (in vitro; mechanistically coherent; indirect inference for ME/CFS) Integrated into:: Wound healing integration guide for ch06-energy-metabolism
35 Abhimanyu et al. 2021 — Post-Infectious Epigenetics Impairs Both Inflammation and Wound Repair
Full Citation:: Abhimanyu, Ontiveros CO, Guerra-Resendez RS, et al. Reversing Post-Infectious Epigenetic-Mediated Immune Suppression. Frontiers in Immunology. 2021;12:688132. DOI:: 10.3389/fimmu.2021.688132 PMID:: 34163486 Study Design:: Mechanistic review of epigenetic immune suppression and reversal strategies Key Findings::
- Post-infectious epigenetic scars (detrimental marks after sepsis, TB, viral infections) produce long-lasting immune suppression
- The suppression affects both pro-inflammatory cytotoxicity AND the wound repair arm of immunity
- AMPK-mTOR, NFAT, NR4A pathway modulation and HDAC inhibitors can partially reverse these changes
- Immune response must balance cytotoxicity with wound repair; post-infectious states dysregulate this balanceConclusion:: ME/CFS as a post-infectious condition with documented epigenetic immune changes (trained immunity dysregulation) would, by this mechanism, have impaired wound repair capacity as part of the same epigenetic suppression that impairs NK cytotoxicity. Wound healing impairment is not a separate prediction but co-results from the same causal chain. Limitations:: Review; ME/CFS-specific epigenetic data limited; AMPK-mTOR and HDAC data mostly in animal models. Certainty:: 0.60 (review; mechanism well-supported; ME/CFS applicability is inferential) Integrated into:: Wound healing integration guide for ch06-energy-metabolism